On 23 October 2026, 宝ホールディングス published the results of an investigation into matters of uncertainty concerning the accounting treatment of its consolidated subsidiary, Takara Bio USA, Inc., as a timely disclosure.
On 23 October 2026, 宝ホールディングス published the results of an investigation into matters of uncertainty concerning the accounting treatment of its consolidated subsidiary, Takara Bio USA, Inc. The publication was made as a timely disclosure and can be understood as part of the verification of the subsidiary's accounting treatment. The materials published on Nikkei Company Information DIGITAL include specific details and conclusions of the investigation, but no additional explanation can be confirmed in the article.
This news is limited to the fact that the results of an investigation into accounting issues that could affect the consolidated financial results of 宝ホールディングス, including Takara Bio USA, Inc., have been published.